Aerovate Therapeutics, Inc.
NASDAQ:AVTE
2.72 (USD) • At close November 4, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0.096 | 0.068 | 0.015 | 0.001 | 0 |
| Gross Profit
| -0.096 | -0.068 | -0.015 | -0.001 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 64.219 | 38.622 | 14.987 | 7.94 | 3.112 |
| General & Administrative Expenses
| 17.19 | 14.615 | 8.035 | 0.949 | 0.218 |
| Selling & Marketing Expenses
| -0.096 | 0 | 0 | 0 | 0 |
| SG&A
| 17.19 | 14.615 | 8.035 | 0.949 | 0.218 |
| Other Expenses
| 0 | -0.079 | -0.003 | -0.647 | 0.001 |
| Operating Expenses
| 81.409 | 53.237 | 23.022 | 8.889 | 3.331 |
| Operating Income
| -81.409 | -53.237 | -23.022 | -8.889 | -3.331 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 5.944 | 1.751 | 0.062 | -0.722 | 0.001 |
| Income Before Tax
| -75.465 | -51.486 | -22.96 | -9.611 | -3.33 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0.056 | 0.025 | 0.003 | -0.572 | 0.001 |
| Net Income
| -75.521 | -51.511 | -22.963 | -9.039 | -3.33 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 |
| EPS
| -2.87 | -2.1 | -0.94 | -0.37 | -0.14 |
| EPS Diluted
| -2.87 | -2.1 | -0.94 | -0.37 | -0.14 |
| EBITDA
| -81.313 | -53.169 | -23.007 | -9.535 | -3.33 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 |